Zoetis Inc. (NYSE:ZTS) Shares Sold by MTM Investment Management LLC

MTM Investment Management LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.9% in the third quarter, HoldingsChannel reports. The fund owned 4,419 shares of the company’s stock after selling 228 shares during the quarter. MTM Investment Management LLC’s holdings in Zoetis were worth $840,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Advisors Asset Management Inc. grew its position in Zoetis by 2.3% during the third quarter. Advisors Asset Management Inc. now owns 17,520 shares of the company’s stock valued at $3,423,000 after acquiring an additional 388 shares during the period. Howe & Rusling Inc. lifted its stake in shares of Zoetis by 8.8% in the 3rd quarter. Howe & Rusling Inc. now owns 1,638 shares of the company’s stock valued at $320,000 after purchasing an additional 132 shares in the last quarter. NS Partners Ltd lifted its stake in shares of Zoetis by 1.7% in the 3rd quarter. NS Partners Ltd now owns 165,788 shares of the company’s stock valued at $32,392,000 after purchasing an additional 2,817 shares in the last quarter. Kirtland Hills Capital Management LLC grew its holdings in shares of Zoetis by 6.1% during the 3rd quarter. Kirtland Hills Capital Management LLC now owns 8,590 shares of the company’s stock worth $1,678,000 after purchasing an additional 497 shares during the period. Finally, Strategy Asset Managers LLC increased its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.5 %

Shares of NYSE ZTS opened at $175.57 on Wednesday. The firm has a market cap of $79.21 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock’s 50-day simple moving average is $186.47 and its 200-day simple moving average is $180.51.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.